News

Balt receives IDE approval from the FDA to begin the STEM Trial

Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma.

Discover the Press Release

Other News

News
Oct 18, 2022

French Government Grant for Research & Development

Read More
French Government Grant for Research & Development
News
Jun 15, 2022

John Allison joins Balt’s Executive Team

Read More
John Allison joins Balt’s Executive Team
News
Jun 01, 2022

Opening of new offices in Paris!

Read More
Opening of new offices in Paris!
News
Dec 09, 2021

Balt Appoints Jeffrey Sachs Chief Legal & Compliance Officer

Read More
Balt Appoints Jeffrey Sachs Chief Legal & Compliance Officer
News
Oct 11, 2021

Balt opens new corporate office in Boston

Read More
Balt opens new corporate office in Boston
Press
Jul 28, 2021

Balt Completes Enrollment in FIRST Study

Read More
Balt Completes Enrollment in FIRST Study
Previous Next
EN